Core Viewpoint - Frontier Biotech has a diversified pipeline in the small nucleic acid field, with varying competitive landscapes and potential indications across different therapeutic areas [1] Group 1: Collaboration and Strategy - The decision for global rights licensing is based on a comprehensive assessment of the partner, product, and industry competition [1] - GSK possesses extensive R&D experience and a professional clinical development team in the therapeutic area of the partnered product [1] - A close communication mechanism has been established between the two companies to maximize product value efficiently [1] Group 2: Product Development Potential - The partnered product has potential for multi-indication development, which can be accelerated by leveraging GSK's global resources [1] - This collaboration aims to explore the potential of other indications more rapidly, thereby enhancing the realization of product value [1]